Patents by Inventor Thomas C. Malone

Thomas C. Malone has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SUBSTITUTED 1,2,3,4-TETRAHYDROPYRIDO[3,4-E] PYRROLO[1,2-A]PYRIMIDINES AS KINASE INHIBITORS
    Publication number: 20160096837
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Application
    Filed: October 7, 2014
    Publication date: April 7, 2016
    Inventors: Clarence Eugene Hull, III, Thomas C. Malone
  • KINASE INHIBITORS
    Publication number: 20160096832
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Application
    Filed: October 6, 2014
    Publication date: April 7, 2016
    Inventors: Julie Wurster, Richard Yee, Clarence Eugene Hull III, Thomas C. Malone
  • Indole-1-Carboxamides as Kinase Inhibitors
    Publication number: 20160096828
    Abstract: This invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, and X are as defined herein. The compounds of Formula I are useful as receptor tyrosine kinase (RTK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases.
    Type: Application
    Filed: October 7, 2014
    Publication date: April 7, 2016
    Inventors: Sougato Boral, Thomas C. Malone, Shimiao Wang
  • Piperidylpyrimidine derivatives as modulators of protein kinase inhibitors and of vascular endothelial growth factor receptor 2
    Patent number: 9296747
    Abstract: This invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein X, R1, R2, R3, R4, R5, R6 and R7 are as defined herein. The compounds of Formula I are useful as protein kinase (PK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, metabolic diseases inflammatory disorders and neurodegenerative disorders.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: March 29, 2016
    Assignee: Allergan, Inc.
    Inventors: Julie A. Wurster, Thomas C. Malone, Clarence Eugene Hull, III, Sandhya Rao, Rong Yang, Richard Yee
  • Substituted 1,2,3,4-tetrahydrobenzo[C][2,7] naphthyridines and derivatives thereof as kinase inhibitors
    Patent number: 9255096
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: October 7, 2014
    Date of Patent: February 9, 2016
    Assignee: Allergan, Inc.
    Inventors: Clarence Eugene Hull, III, Thomas C. Malone
  • Kinase inhibitors
    Patent number: 9233968
    Abstract: Described herein are compounds which in some embodiments are capable of modulating, regulating, and/or inhibiting tyrosine kinase signal transduction, as well as methods and compositions related to the compounds.
    Type: Grant
    Filed: October 27, 2014
    Date of Patent: January 12, 2016
    Assignee: Allergan, Inc.
    Inventors: Sougato Boral, Shimiao Wang, Thomas C. Malone
  • Biodegradable intravitreal tyrosine kinase implants
    Patent number: 9233070
    Abstract: Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants can be placed in an eye to treat or reduce the occurrence of one or more ocular conditions.
    Type: Grant
    Filed: August 19, 2013
    Date of Patent: January 12, 2016
    Assignee: Allergan, Inc.
    Inventors: Jeffrey L. Edelman, Patrick M. Hughes, Thomas C. Malone, Gerald W. DeVries, Joan-En Chang-Lin, Jane-Guo Shiah, Thierry Nivaggioli, Lon T. Spada, Wendy M. Blanda
  • PORTABLE TRANSCEIVER WITH VEHICLE SECURITY CONTROL AND LOCATE FEATURES
    Publication number: 20150283976
    Abstract: A portable transceiver for locking and locating an automobile, includes a remote keyless entry system for locking the automobile; a locating device determining a location of the transceiver, wherein the remote keyless entry system and the locating device are housed in a pocket sized housing; and a processor deriving directional information from a current location to a waypoint, wherein in response to an activation of the remote keyless entry system, the locating device determines the waypoint corresponding substantially to that of the automobile.
    Type: Application
    Filed: June 19, 2015
    Publication date: October 8, 2015
    Inventors: THOMAS C. MALONE, JAMES R. TRANCHINA, JOHN DiCROCE, SHANE WILSON
  • Portable transceiver with vehicle security control and locate features
    Patent number: 9063833
    Abstract: A portable transceiver for locking and locating an automobile, includes a remote keyless entry system for locking the automobile; a locating device determining a location of the transceiver, wherein the remote keyless entry system and the locating device are housed in a pocket sized housing; and a processor deriving directional information from a current location to a waypoint, wherein in response to an activation of the remote keyless entry system, the locating device determines the waypoint corresponding substantially to that of the automobile.
    Type: Grant
    Filed: February 15, 2013
    Date of Patent: June 23, 2015
    Assignee: VOXX INTERNATIONAL CORPORATION
    Inventors: Thomas C. Malone, James R. Tranchina, John DiCroce, Shane Wilson
  • SUBSTITUTED 3-(5-MEMBERED UNSATURATED HETEROCYCLYL-1, 3-DIHYDRO-INDOL-2-ONE'S AND DERIVATIVES THEREOF AS KINASE INHIBITORS
    Publication number: 20150099746
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Application
    Filed: October 16, 2014
    Publication date: April 9, 2015
    Inventors: Xialing Guo, Zhen Zhu, Thomas C. Malone
  • Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
    Patent number: 8968766
    Abstract: Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions.
    Type: Grant
    Filed: February 26, 2013
    Date of Patent: March 3, 2015
    Assignee: Allergan, Inc.
    Inventors: Patrick M. Hughes, Thomas C. Malone, Gerald W. DeVries, Jeffrey L. Edelman, Joan-En Lin, Jane-Guo Shiah, Thierry Nivaggioli
  • 3-phenyl-5-ureidoisothiazole-4-carboximide and 3-amino-5-phenylisothiazole derivatives as kinase inhibitors
    Patent number: 8969583
    Abstract: This invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R, R1, R2, R3, n, X1, X2, L1, and L2 are as defined herein. The compounds of Formula I are useful as receptor tyrosine kinase (RTK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases.
    Type: Grant
    Filed: December 27, 2012
    Date of Patent: March 3, 2015
    Assignee: Allergan, Inc.
    Inventors: Thomas C. Malone, C. Eugene Hull, Sougato Boral, Julie A. Wurster, Michael R. Robinson, Jeffrey L. Edelman
  • 4-PREGENEN-11BETA-17-21-TRIOL-3,20-DIONE DERIVATIVES
    Publication number: 20150057258
    Abstract: The present invention relates to novel 4-pregenen-11?-17-21-triol-3,20-dione derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals, as modulators of glucocorticoid or mineralocorticoid receptors. The invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat disorders associated with glucocorticoid or mineralocorticoid receptor modulation.
    Type: Application
    Filed: November 5, 2014
    Publication date: February 26, 2015
    Inventors: Jeffrey L. Edelman, Alissar Nehme, Thomas C. Malone
  • SUBSTITUTED 3-(5-MEMBERED UNSATURATED HETEROCYCLYL-1, 3-DIHYDRO-INDOL-2-ONE'S AND DERIVATIVES THEREOF AS KINASE INHIBITORS
    Publication number: 20150018310
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Application
    Filed: September 29, 2014
    Publication date: January 15, 2015
    Inventors: Xialing Guo, Zhen Zhu, Thomas C. Malone, Julie Wurster
  • 4-pregenen-11?-17-21-triol-3,20-dione derivatives
    Patent number: 8906892
    Abstract: The present invention relates to novel 4-pregenen-11?-17-21-triol-3,20-dione derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals, as modulators of glucocorticoid or mineralocorticoid receptors. The invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat disorders associated with glucocorticoid or mineralocorticoid receptor modulation.
    Type: Grant
    Filed: November 9, 2012
    Date of Patent: December 9, 2014
    Assignee: Allergan, Inc.
    Inventors: Jeffrey L. Edelman, Alissar Nehme, Thomas C. Malone
  • Kinase inhibitors
    Patent number: 8889870
    Abstract: The present invention relates to compounds of formulae I and II wherein the variables are as defined herein. These compounds are capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: November 18, 2014
    Assignee: Allergan, Inc.
    Inventors: Clarence E. Hull, III, Thomas C. Malone
  • Substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-ones and derivatives thereof as kinase inhibitors
    Patent number: 8877923
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: November 4, 2014
    Assignee: Allergan, Inc.
    Inventors: Xialing Guo, Zhen Zhu, Thomas C. Malone
  • Substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-one's and derivatives thereof as kinase inhibitors
    Patent number: 8865682
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: November 15, 2012
    Date of Patent: October 21, 2014
    Assignee: Allergan, Inc.
    Inventors: Xialing Guo, Zhen Zhu, Thomas C. Malone, Julie Wurster
  • KINASE INHIBITORS
    Publication number: 20140256819
    Abstract: The present invention relates to compounds of formula I or a pharmaceutically acceptable salts thereof; wherein the variables R1-R5, Ar1, and X are as defined herein. The compounds are capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Application
    Filed: March 6, 2014
    Publication date: September 11, 2014
    Applicant: Allergan, Inc.
    Inventors: Thomas C. Malone, C. Eugene Hull, III
  • Biodegradable Intravitreal Tyrosine Kinase Implants
    Publication number: 20140031408
    Abstract: Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants can be placed in an eye to treat or reduce the occurrence of one or more ocular conditions.
    Type: Application
    Filed: August 19, 2013
    Publication date: January 30, 2014
    Applicant: Allergan, Inc.
    Inventors: Jeffrey L. Edelman, Patrick M. Hughes, Thomas C. Malone, Gerald W. DeVries, Joan-En Chang-Lin, Jane-Guo Shiah, Thierry Nivaggioli, Lon T. Spada, Wendy M. Blanda